Soluble form of a receptor for advanced glycation end products sRAGE as a biomarker
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
There is a growing body of evidence that advanced glycation end products (AGEs) and their receptor (RAGE) system are implicated in various disorders, including vascular complications in diabetes, cardiovascular disease, neurodegenerative diseases, inflammatory and autoimmune disorders, and cancer growth and metastasis. Indeed, the engagement of RAGE with AGEs elicits oxidative stress generation and evokes inflammatory and thrombogenic responses, thus playing an important role in these devastating disorders. Moreover, since administration of a recombinant soluble form of RAGE (sRAGE), has been shown to block the AGE-RAGE signaling pathway in animal models, exogenously administered sRAGE may capture and eliminate circulating AGEs, thus protecting against the AGE-elicited tissue damage by acting as a decoy receptor for AGEs. Recently, sRAGE has been identified in humans. However, there are a few comprehensive papers about the regulation and role of sRAGE in humans. Therefore, in this paper, we review the kinetics, regulation and pathophysiological role of sRAGE in humans. We further discuss the potential clinical utility of measuring sRAGE in various disorders as a biomarker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Soro-Paavonen, A., Watson, A. M. D., Li, J., Paavonen, K., Koitka, A., Calkin, A. C., Barit, D., Coughlan, M. T., Drew, B. G., Lancaster, G. I., et al. (2008) · Diabetes · doi:10.2337/db07-1808 · Cited by 407
Maillard-Lefebvre, H., Boulanger, E., Daroux, M., Gaxatte, C., Hudson, B. I., & Lambert, M. (2009) · Rheumatology · doi:10.1093/rheumatology/kep199 · Cited by 190
Yamagishi, S.-I., Adachi, H., Nakamura, K., Matsui, T., Jinnouchi, Y., Takenaka, K., Takeuchi, M., Enomoto, M., Furuki, K., Hino, A., et al. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.007 · Cited by 148
Self-citationNakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Ueda, Y., Suzuki, T., Yamada, S., Takeuchi, M., Fukami, K., Ueda, S., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.05.018 · Cited by 53
Self-citationNakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Suzuki, T., Ueda, Y., Yamada, S., Shoji, H., Takeuchi, M., Ueda, S., et al. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.05.002 · Cited by 46
Self-citation
Cited by
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
The biphasic function of microglia in ischemic stroke
Ma, Y., Wang, J., Wang, Y., & Yang, G.-Y. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.005 · Cited by 655
Inflammation and type 2 diabetes
Calle, M. C., & Fernandez, M. L. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.11.006 · Cited by 488
Perrone, A., Giovino, A., Benny, J., & Martinelli, F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/3818196 · Cited by 459
RAGE regulation and signaling in inflammation and beyond
Kierdorf, K., & Fritz, G. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1012519 · Cited by 428
Metadata
- Authors
- Yamagishi, S.-I.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2010
- Volume
- E2
- Issue
- 4
- Pages
- 1184-1195
- ISSN
- 1944-7892 (ISSN-L)
- 1945-0494
- 1945-0508
- DOI
- 10.2741/e178
- OpenAlex
- W2013463636
- Cited by
- 130
- References
- 6
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.